Clinical consensus guidelines on the application of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: recommendations of the Irish Network for Biomarkers in Neurodegeneration

Simple item page
dc.contributor.authorMiller, A.-M.
dc.contributor.authorBegley, E.
dc.contributor.authorCoen, R.
dc.contributor.authorDoyle, M.
dc.contributor.authorDunne, J.
dc.contributor.authorHutchinson, S.
dc.contributor.authorKennelly, S. P.
dc.contributor.authorKenny, R. A.
dc.contributor.authorKilleen, R.
dc.contributor.authorLynch, A.
dc.contributor.authorO'Dwyer, S.
dc.contributor.authorO'Neill, Cora
dc.contributor.authorO'Sullivan, S.
dc.contributor.authorRowan, M.
dc.contributor.authorSheehy, N.
dc.contributor.authorMcGuigan, C.
dc.contributor.authorLawlor, Brian A.
dc.contributor.funderHorizon 2020en
dc.contributor.funderHealth Research Boarden
dc.date.accessioned2018-04-27T11:18:41Z
dc.date.available2018-04-27T11:18:41Z
dc.date.issued2016-11
dc.date.updated2018-04-27T11:06:08Z
dc.description.abstractIt is accepted that a lumbar puncture (LP) and cerebrospinal fluid (CSF) biomarker analysis support the routine diagnostic work-up for the differential diagnosis of dementia due to Alzheimer’s disease (AD) within certain patient cohorts1. These tests, which measure CSF protein concentrations of amyloid-β42 (Aβ42), total tau (t-tau) and phospho tau (p-tau), were recently validated, accredited and made available clinically for the first time in Ireland. A working group, comprising Irish clinical and scientific researchers, met to review a) the validation results; b) international consensus opinions, and c) research and clinical evidence as to the clinical utility of CSF biomarker analysis for AD dementia diagnosis. The outcome of this meeting was the formulation of a consensus statement paper for the benefit of health care professionals involved in the diagnosis and management of dementia to ensure appropriate use of these biomarker tests in clinical settings in Ireland.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid483
dc.identifier.citationMiller, A.-M., Begley, E., Coen, R., Doyle, M., Dunne, J., Hutchinson, S., Kennelly, S. P., Kenny, R. A., Killeen, R., Lynch, A., O'Dwyer, S., O'Neill, C., O'Sullivan, S., Rowan, M., Sheehy, N., McGuigan, C. and Lawlor, B. A. (2016) 'Clinical consensus guidelines on the application of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: recommendations of the Irish Network for Biomarkers in Neurodegeneration', Irish Medical Journal, 109(10), 483 (12pp). doi:10147/621025en
dc.identifier.doi10147/621025
dc.identifier.issn0332-3102
dc.identifier.issued10en
dc.identifier.journaltitleIrish Medical Journalen
dc.identifier.urihttps://hdl.handle.net/10468/5894
dc.identifier.volume109en
dc.language.isoenen
dc.publisherIrish Medical Organisationen
dc.relation.ispartofhttp://imj.ie/novemberdecember-2016-vol-109-no-10/
dc.relation.projectinfo:eu-repo/grantAgreement/EC/H2020::ERA-NET-Cofund/643417/EU/ERA-NET for establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020/JPco-fuNDen
dc.rights© 2016, Irish Medical Journal. All rights reserved.en
dc.subjectAlzheimer's diseaseen
dc.subjectNeuroscienceen
dc.titleClinical consensus guidelines on the application of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: recommendations of the Irish Network for Biomarkers in Neurodegenerationen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clinical_Consensus_Guidelines.pdf
Size:
214.22 KB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Biochemistry and Cell Biology - Journal Articles